Sinoretik Fort

Quick links to important sections

Sinoretik Fort

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinoretik Fort

Sinoretik Fort is a prescription-only medicine classified as an antihypertensive agent used for the management of high blood pressure in adults. It is supplied as an oral preparation in a tablet form. This preparation is defined as a Fixed-dose combination (FDC) because it contains two distinct, synthetic active compounds, targeting arterial hypertension through a dual mechanism of action.

Property Description
Active ingredients Lisinopril and Hydrochlorothiazide (HCTZ)
Form Tablet (Oral preparation)
Pharmacological class ACE Inhibitor and Diuretic combination
Common use Management of essential hypertension
Origin Synthetic

Definition and Pharmacological Classification

Sinoretik Fort belongs to the ACE Inhibitor and Diuretic combination pharmacological class, a pairing clinically recognized for its ability to provide superior blood pressure lowering effects compared to either ingredient used alone. This combination therapy is typically utilized for adult patients whose essential hypertension has not been adequately controlled by therapy with a single agent. Combining an Angiotensin-Converting Enzyme inhibitor with a thiazide diuretic is an established approach for managing blood pressure.


Dual Active Ingredients: Composition and Origin

Its core consists of two synthetic active ingredients: Lisinopril, which functions as an Angiotensin-Converting Enzyme (ACE) inhibitor, and Hydrochlorothiazide (HCTZ), a Thiazide diuretic. The combination works by blocking a substance that constricts blood vessels while simultaneously helping the kidneys remove excess salt and water. This pairing in an FDC ensures that both the vascular resistance and the fluid volume are managed concurrently, offering a comprehensive systemic approach.


General Purpose of This Combination Therapy

The general purpose of Sinoretik Fort is to provide rigorous control over systemic blood pressure through its complementary therapeutic actions. A differentiating factor is the "Fort" designation, which commonly indicates a higher concentration of one or both active ingredients compared to the standard Sinoretik formulation. This concentrated formulation is employed for patients requiring a more intensive initial therapeutic effect, leveraging the synergistic potential of its components to maintain blood pressure within a target range.

Regulatory References

  1. Lisinopril and Hydrochlorothiazide Drug Information
  2. Benefits of Combined Therapy for Hypertension (PubMed)

What side effects are possible with Sinoretik Fort?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety characteristics of the lisinopril/hydrochlorothiazide combination as officially documented in government regulatory sources. Adverse reactions are classified by frequency and affected organ system.

Frequency-Classified Adverse Reactions

Classification Common Examples (Affection ge 1/100 to < 1/10)
Nervous System Dizziness, headache
Respiratory Cough (often dry and persistent)
Vascular Orthostatic effects (low blood pressure upon standing)
General Disorders Fatigue, asthenia (weakness)

Uncommon effects, reported in ge 1/1,000 to < 1/100 of patients, include palpitations, rash, and sleep disturbances.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for serious reactions, including angioedema (swelling of the face, tongue, or throat), which is rare but requires immediate attention. Other very rare but serious events documented across the System-Organ Classes (SOC) include hepatic failure, acute renal failure, and severe blood disorders (e.g., agranulocytosis).

Population-Specific and High-Level Restrictions:

  • Pregnancy: The medication is contraindicated during pregnancy, particularly the second and third trimesters, due to risks of injury or death to the developing fetus, as noted in FDA warnings.

  • Contraindications: Use is restricted in patients with anuria (inability to pass urine) and in those with hypersensitivity to sulfonamide-derived drugs. The combination is also contraindicated with certain other blood pressure medicines, like aliskiren (in diabetic patients) and Neprilysin inhibitors, due to documented safety risks.

  • Time-Related Patterns: Symptomatic low blood pressure upon standing is noted as being more common in patients who are volume-depleted or salt-depleted.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes overdose with Sinoretik Fort (lisinopril/hydrochlorothiazide) as an extreme exaggeration of its intended effects, requiring immediate medical attention. The most frequent and serious documented manifestation is severe hypotension (critically low blood pressure), which can progress to circulatory shock. The diuretic component can cause severe fluid loss and electrolyte derangements, including hypokalemia (low potassium) and hyponatremia (low sodium).

Other officially documented signs of overdose include drowsiness, confusion, tachycardia (rapid heart rate), and acute renal failure as a serious complication of poor blood flow to the kidneys. The extreme outcomes listed in regulatory sources include coma and seizures.

Severe Manifestation Required Action
Severe Hypotension Place in supine position; IV fluid administration may be needed.
Collapse, Seizure, or Coma Contact emergency medical services immediately.

Regulatory authorities state that management is entirely symptomatic and supportive. There is no specific antidote known for this combination product. Management procedures may include gastric lavage or administration of activated charcoal for recent ingestions, along with intensive monitoring of vital signs, fluid balance, and serum electrolytes in a hospital setting.

Therapeutic Uses of Sinoretik Fort

Sustained Control of Essential Hypertension

This fixed-dose combination is commonly used in the long-term management of essential hypertension, a condition presenting with chronically elevated systolic and diastolic blood pressure readings in adults. This therapy may be applied in clinical contexts where the management of these high-pressure readings requires a dual therapeutic approach, often succeeding where a single blood pressure agent has been insufficient. The primary therapeutic support contributes to maintaining target control over elevated pressures and is considered relevant for providing support in the area of **cardiovascular risk reduction.

Reduction of Cardiovascular and Organ Risk

By effectively and continuously lowering high blood pressure, the medication may assist with easing the physiological strain on vital organs like the heart, brain, and kidneys. This assists with managing the risk of future cardiovascular events, such as a stroke or heart attack (myocardial infarction), and may support the maintenance of functional stability in organs like the kidneys. The medication's primary indications include the management of essential hypertension and the subsequent reduction of risks associated with high pressure in key organ systems.


Quick Fact: Support for Chronic Pressure The combination is applied in settings where patients require long-term, continuous assistance to manage the systemic burden associated with high blood pressure, thereby easing the physiological strain on vital organs.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Sinoretik Fort?

Official regulatory documents establish strict population eligibility rules for Sinoretik Fort (Lisinopril/Hydrochlorothiazide). The medicine is approved for adults managing essential hypertension who require a fixed-dose combination. Use is contraindicated in several groups due to severe risks and specific physiological states, as defined below.

Absolute Contraindications

Population Condition
Pregnancy Second and third trimesters. Must be discontinued immediately if pregnancy is detected.
Organ Function Anuria, severe renal impairment (Creatinine Clearance <30 ml/ min), or severe hepatic impairment.
Hypersensitivity History of angioedema (related to any ACE inhibitor, hereditary, or idiopathic) or allergy to sulfonamide-derived drugs.
Concomitant Therapy Patients taking Aliskiren (with diabetes or renal impairment) or those not observing the required 36-hour wash-out period from Sacubitril/Valsartan.

Restricted and Non-Established Use

Population Status
Pediatric Not recommended; safety and efficacy have not been established in patients under 18 years of age.
Moderate Renal Impairment Restricted use; the fixed combination should not be administered until the individual components have been titrated to establish the necessary dose.
Lactation Not recommended; official data is insufficient to determine infant risk during breastfeeding.
Special Conditions Use requires caution in patients with Aortic or Mitral Valve Stenosis and those who are volume- or salt-depleted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sinoretik Fort's interaction profile is documented primarily by pharmacodynamic considerations, particularly concerning dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) and effects on electrolyte balance. Co-administration with Sacubitril/Valsartan is formally contraindicated due to the high risk of angioedema, requiring a mandatory 36-hour separation period. The medicine is also contraindicated with Aliskiren in patients with concurrent diabetes or established renal impairment.

Interaction Category Interacting Substances Official Documented Outcome
High Hyperkalemia Risk Potassium Supplements, Potassium-Sparing Diuretics, Trimethoprim Increased risk of elevated serum potassium (Hyperkalemia).
Increased Safety Risk mTOR Inhibitors, Injectable Gold Increased risk of Angioedema; reported Nitritoid Reactions.
Efficacy & Renal Risk NSAIDs, Lithium Potential for reduced antihypertensive effect and increased risk of Lithium toxicity or renal impairment.

Regarding substances, consumption of Alcohol may potentiate the effect of the medicine, increasing the documented risk of orthostatic hypotension. Conversely, regulatory documents note that taking the tablets with food has no significant effect on the bioavailability of either active ingredient. Furthermore, pharmacokinetic notes state that systemic drug exposure (AUC) is documented to be higher in both elderly patients and those with significantly impaired renal function.

Mechanism of Action

Sinoretik Fort is a fixed-dose combination product containing lisinopril and hydrochlorothiazide, modulating two distinct physiological systems.

Lisinopril Mechanism

Lisinopril acts as a competitive inhibitor of the angiotensin-converting enzyme (ACE), a peptidyl dipeptidase. ACE is primarily responsible for converting the inactive decapeptide angiotensin I to the potent octapeptide angiotensin II. By inhibiting this conversion, lisinopril decreases systemic angiotensin II plasma concentrations. This reduction subsequently lessens the vasoconstrictive effect mediated by angiotensin II type 1 ( AT1) receptors on vascular smooth muscle, and attenuates aldosterone secretion from the adrenal cortex. Lowered aldosterone activity in the renal collecting ducts leads to decreased sodium and water reabsorption, contributing to a fluid shift. Furthermore, ACE is also known as kininase II, an enzyme that inactivates the vasodilator bradykinin; its inhibition by lisinopril results in increased local bradykinin levels, which further promotes vasodilation.

Hydrochlorothiazide Mechanism

Hydrochlorothiazide is a thiazide diuretic that primarily targets the distal convoluted tubule of the nephron. It functions by inhibiting the sodium-chloride cotransporter (NCCT) on the apical membrane. This inhibition reduces the reabsorption of Na^+ and Cl^- electrolytes, resulting in an increased osmotic load within the renal tubular lumen. This downstream effect increases the excretion of Na^+, Cl^-, and water. The ultimate systemic physiological consequence of the combined action of both components is a reduction in both peripheral vascular resistance and total intravascular fluid volume.

Dosage and Administration Information

The administration of Sinoretik Fort, a fixed-dose oral combination of lisinopril and hydrochlorothiazide, is structured for use strictly for maintenance therapy in adults.

Administration Scope

Parameter Instruction
Route of Administration The medicine is taken orally as a tablet.
Dosing Schedule The combination is not indicated for initial treatment; it is reserved for patients whose blood pressure is not adequately controlled on monotherapy. Maximum dose is Lisinopril 80 mg / HCTZ 50 mg once daily.
Frequency and Timing It must be administered once daily at approximately the same time each day. The dose can be taken with or without food.
Preparation Details The tablet should be swallowed whole and must not be broken, crushed, or chewed.
Special Populations The combination is contraindicated in patients with severe renal impairment (creatinine clearance leq 30 mL/min). Safety and effectiveness have not been established for use in pediatric patients.
Procedural Condition Diuretic therapy should ideally be discontinued for 2 to 3 days prior to initiating the FDC to reduce the risk of acute hypotension.
Missed Dose Rule If a dose is missed, it should be skipped if it is almost time for the next scheduled dose; patients must not double the dose.

Summary of Use Protocol

The entire protocol defines the medicine as a standardized once-daily oral treatment intended solely for maintenance use in adults with established hypertension. This structure involves prior monotherapy failure and requires adherence to renal function limits. Dose titration intervals of 2 to 4 weeks must pass before any dosage increase is made.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines key clinical studies that have been conducted on the drug. This information does not replace professional medical guidance.

The primary studies have investigated the drug's use in relation to blood pressure and symptoms.


Key Clinical Trial Results

Phase III Efficacy Trials

Phase III trials have examined the drug's effect on blood pressure control. One study reported findings regarding the change in systolic and diastolic blood pressure over the study period.

  • In a multi-center, randomized, controlled trial (RCT), participants receiving the drug were compared to those receiving a placebo over a 12-week period. The primary endpoint was a change in blood pressure metrics.

Comparative Study Data

A comparative study indicated that the drug was evaluated against the current standard of care for hypertension management.

  • The study's design was non-inferiority, which involves an analysis against an established treatment. The analysis focused on predefined measures of blood pressure changes over 6 months.

Extended Research

Long-term Safety and Tolerability

The drug was evaluated for long-term use in several studies, including those following patients for up to two years to collect data on specific events and changes in laboratory parameters over time. The study evaluated whether continued administration was associated with changes in safety profiles.

Combination Therapy Research

Research has explored whether combining the drug with other antihypertensives was associated with differences in specific patient measurements. These studies investigate the potential role of the drug as part of a multi-drug regimen.

Overall, the evidence base consists of multiple studies that have investigated the drug's use.

Key Studies & References

  1. A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal | ClinicalTrials.gov (NCT00219063)

Frequently Asked Questions (FAQ)

Common questions about Sinoretik Fort (FAQ)


Q: What is the main reason a doctor would prescribe Sinoretik Fort?

A: According to official regulatory documents, this medicine is indicated for the treatment of essential hypertension (high blood pressure). It is typically reserved for patients whose blood pressure is not adequately controlled on monotherapy, meaning they have previously used either lisinopril or hydrochlorothiazide alone without success.


Q: How is Sinoretik Fort different from regular Sinoretik?

A: The 'Fort' designation typically indicates a higher concentration of the active ingredients (lisinopril and hydrochlorothiazide) compared to a standard Sinoretik formulation. This concentrated formulation is often utilized when a more intensive therapeutic effect is desired.


Q: Why is the 'Fort' version stronger than the regular version?

A: The combination is available in a higher dose strength to provide more intensive blood pressure control. This strength is utilized for patients when a lower, single-dose strength of the combined ingredients has proven insufficient to achieve their established blood pressure goals.


Q: Do I need to change my diet when taking Sinoretik Fort?

A: Since the medicine contains a diuretic, it can affect the body's electrolyte levels, including sodium and potassium. Official product information suggests that the intake of these electrolytes (e.g., dietary salt and potassium) is generally a topic for discussion with a healthcare professional.


Q: Is it normal to urinate more frequently when taking this drug?

A: Yes, increased urination is an expected effect. The medicine contains a diuretic, hydrochlorothiazide, which works by causing the kidneys to remove unneeded water and salt from the body. Increased urination (diuresis) can begin within a couple of hours after administration.


Q: Can Sinoretik Fort cause dry mouth or thirst?

A: According to official drug information, dry mouth and thirst are listed as possible side effects. These symptoms may be indicators of a temporary disturbance in your body's fluid or mineral balance.


Q: Does Sinoretik Fort interact with supplements like potassium or magnesium?

A: The drug is known to interact with certain substances. Potassium supplements and salt substitutes containing potassium are listed as an interacting substance that may lead to significant increases in serum potassium levels. Magnesium is not specifically addressed as a common interaction in official documents.


Q: Does official guidance mention anything about driving while using Sinoretik Fort?

A: Official guidance warns that the medicine may cause occasional dizziness or tiredness. These side effects can affect the ability to drive or operate heavy machinery, particularly when treatment is first started, the dose is changed, or when the medicine is taken with alcohol.


Q: Can Sinoretik Fort affect my blood sugar levels?

A: Regulatory information indicates that the diuretic component, hydrochlorothiazide, may cause an increase in the amount of sugar (glucose) in the blood, which is known as hyperglycemia. Patients with pre-existing diabetes require careful evaluation.


Q: Can Sinoretik Fort affect my cholesterol levels?

A: Official reports show that increases in cholesterol and triglyceride levels may be associated with the thiazide diuretic component of the therapy. These potential changes are generally monitored as part of ongoing treatment.


Q: Why is potassium monitoring often necessary when on this medication?

A: Regular monitoring of serum potassium levels is necessary because the combination of ingredients can affect potassium balance. This is done to ensure levels do not become too high or too low, as this can potentially impact heart function.


Q: If I have a history of gout, is Sinoretik Fort still an option?

A: The thiazide component is noted to potentially precipitate hyperuricaemia and/or gout in certain patients. Regulatory summaries note that caution is required, as dosage adjustment for existing gout medications is sometimes indicated.


Q: Are there warnings about using Sinoretik Fort with alcohol?

A: Official documents note that consuming alcohol can make certain side effects worse. Specifically, the risk of dizziness or feeling faint (orthostatic hypotension) may be increased when alcohol is combined with this medication.


Q: Do any official warnings exist regarding sun exposure while on this drug?

A: Yes, official guidance warns that the drug is associated with an increased risk of certain types of skin and lip cancer (non-melanoma skin cancer). Regulatory documents recommend that skin should be protected from excessive sun exposure and UV rays while taking this medicine.


Q: How quickly does Sinoretik Fort start to lower blood pressure?

A: The antihypertensive activity typically begins to show about one hour after administration, with the peak reduction occurring by six hours. However, achieving the optimal, stable reduction in blood pressure may require continuing therapy for two to four weeks.


Q: What happens if I forget to take Sinoretik Fort one day?

A: Official guidance contains specific rules for a missed dose, including when to take it as soon as possible and when it should be skipped if it is almost time for the next dose. The guidance emphasizes that a double dose should not be taken to compensate for a missed dose.


Q: What is the average duration of the blood pressure-lowering effect?

A: The antihypertensive effects of the medicine are generally maintained for at least 24 hours after a single daily dose, which supports its use as a once-daily treatment. The effect observed at 24 hours may be less pronounced than the peak effect.


Q: Does Sinoretik Fort interact with anti-inflammatory drugs?

A: Yes, a documented interaction exists. Official product information states that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the blood pressure-lowering effect of the medicine. This combination may also increase the risk of developing kidney problems.


Q: Is Sinoretik Fort safe for older people (the elderly)?

A: Official research indicates that the blood pressure response and adverse events in older patients were generally similar to those in younger adults when given comparable doses. However, older patients may show a tendency toward higher blood levels of the components.


Q: Does Sinoretik Fort have any long-term effects on the heart?

A: Lowering blood pressure is a general therapeutic goal that is associated with the potential for reducing the long-term risk of fatal and non-fatal cardiovascular events. These events include stroke and myocardial infarction.


Q: Is Sinoretik Fort a long-term treatment, or is it temporary?

A: Treatment of hypertension is considered a long-term treatment in official patient information. Any decision to interrupt or stop treatment is typically made in consultation with a healthcare provider.


Q: Do I need regular blood tests while I am taking Sinoretik Fort?

A: Regulatory documents indicate that increasing the frequency of medical check-ups may be necessary, particularly during the period when the dosage is being adjusted. Your healthcare provider will determine the necessary frequency of these control examinations.


Q: Has Sinoretik Fort been studied in people with diabetes?

A: Official information mentions that the use of this drug requires caution if a patient suffers from diabetes. Furthermore, the medicine may increase blood sugar, and specific drug combinations are contraindicated in diabetic patients with established kidney issues.


Q: Are there known ethnic differences in how the drug affects people?

A: Official research notes that Black hypertensive patients (who often have a low-renin hypertensive population) showed a smaller average blood pressure response to lisinopril monotherapy than non-Black patients. This information pertains to one of the active ingredients.


Q: Why might a doctor switch me from another medicine to Sinoretik Fort?

A: The fixed-dose combination product is typically prescribed when a patient's blood pressure is unresponsive to monotherapy. This means the patient was likely switched because a single blood pressure agent was insufficient to achieve their treatment goals.


Q: What should I watch out for in terms of muscle cramps while taking it?

A: Official documentation lists muscle cramps and general muscle weakness as possible side effects. These can occasionally be a sign of a disturbed balance of fluids or minerals (electrolytes) in the body.


Q: Can I take other heart medications at the same time as Sinoretik Fort?

A: Clinical studies have examined the active ingredient lisinopril in combination with other common heart medications. Official documents report that lisinopril has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.


Q: Can I take Sinoretik Fort if I have asthma?

A: Official patient information indicates that discussion with a doctor is necessary if a patient has allergy problems or asthma prior to taking the medicine.

How should Sinoretik Fort be stored and disposed of?

How to Store and Dispose of Sinoretik Fort

Storage Requirements

Sinoretik Fort tablets must be stored at Controlled Room Temperature, ideally between 20 C and 25 C (68 F and 77 F). The medication should be kept in the container it came in, with the lid tightly closed.

It is essential to store the medication away from excess heat and moisture and to protect it from direct light. Do not store the tablets in damp areas, such as a bathroom, and prevent freezing.

Child Safety and Disposal

As with all medications, keep Sinoretik Fort out of the reach and sight of children, placing it in a safe location where it is up and away. Always ensure safety caps are locked.

Do not keep outdated or unneeded medication. To ensure proper disposal and minimize harm, consult with a healthcare professional or pharmacist on the best methods for discarding any unused tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinoretik Fort found in:

A-Z Index: